Spermosens presents JUNO-Checked at ASRM 2026 in Baltimore

ASRM brings together clinicians, embryologists, laboratory specialists and companies in reproductive medicine. At the congress, Spermosens will present the JUNO-Checked Generation 3 system, which has been developed for the needs of clinics and laboratories and is currently being evaluated in a clinical validation study at the Reproductive Medicine Center (RMC) in Malmö.

Fertilization depends on a specific molecular interaction, in which IZUMO1 on the sperm binds to JUNO on the egg. Standard semen analysis measures sperm count, motility and morphology, but cannot measure this binding. JUNO-Checked is designed to measure the strength of the binding between sperm and JUNO, the receptor on the egg. In a clinical study completed in 2025 at RMC in Malmö, stronger sperm binding was associated with higher IVF fertilization rates.

Spermosens' strategy is to bring JUNO-Checked to the market through partnerships, in the form of licensing, distribution or co-development agreements with established companies in the fertility field. This approach is designed to reduce the Company's capital needs and give JUNO-Checked access to existing sales channels and customer relationships. Spermosens is in active dialogue with several relevant companies in Europe, the US and Asia, and the congress gives the Company the opportunity to meet both these and new potential partners in person.

Ahead of the congress, Spermosens has also launched a new film explaining how JUNO-Checked works, from the interaction between IZUMO1 and JUNO to the measurement on the biosensor. The film is available at www.spermosens.com and on the Company's YouTube channel.

Tore Duvold, CEO of Spermosens, comments: "This is an exciting time for Spermosens. Being admitted to the New Horizons Pavilion puts JUNO-Checked in front of the clinicians, laboratories and companies that shape fertility care. We are in active dialogue with several companies that see the potential in measuring sperm function, and ASRM gives us the chance to take these conversations further and meet new potential partners. I look forward to showing the Generation 3 system and the clinical results we have achieved so far."

For more information, please contact:
Tore Duvold, CEO
info@spermosens.com

About Spermosens AB

Spermosens AB is a pioneering biotechnology company based in Sweden, focused on advancing fertility diagnostics through science driven solutions. The company develops cutting-edge technologies designed to improve fertility outcomes and streamline treatment pathways for individuals and couples facing infertility. The proprietary product, JUNO-Checked, provides a novel diagnostic approach that enhances precision and evaluations by measuring the sperm-egg binding capacity. JUNO-Checked supports more informed clinical decisions and individualized treatments strategies. Driven by a strong commitment to scientific excellence and patient care, Spermosens collaborates with leading research institutions to deliver transformative fertility diagnostics to the global market. The company's shares are listed on the Spotlight Stock Market under the name SPERM (ISIN code SE0015346424). For more information, see www.spermosens.com.